USA: Researchers have drawn attention to an unusual but potentially distressing adverse effect linked to a commonly used postoperative treatment for non–muscle-invasive bladder cancer (NMIBC).

Draft guidance from NICE recommends durvalumab before and after surgery for muscle-invasive bladder cancer following phase 3 trial survival data.

Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...

By Dr. Sanchari Sinha Dutta, Ph.D. A large electronic health record study suggests that difficulty recognizing painless blood ...

A new Stanford Medicine study reveals that colorblind men face 52% higher bladder cancer death risk because they can't see ...

At 57, two-time Super Bowl champion Deion Sanders, has a brand-new bladder. The University of Colorado coach recently underwent reconstructive surgery to treat an aggressive form of bladder cancer ...

(NEXSTAR) – The earliest symptoms of bladder cancer may go unnoticed by patients with colorblindness or similar color vision deficiencies, a study published in the peer-reviewed journal Nature ...

Bladder cancer is a common cancer and one of the most costly to treat, yet there has been little change in the standard of care in 40 years. This panel will focus on the unmet needs in bladder cancer ...

Bladder cancer, a disease that affects tens of thousands of Americans each year, often begins silently. As cells in the urinary bladder grow uncontrollably, they can form tumors and, if left unchecked ...

Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical ...

Interim clinical data has exceeded the recommended guidelines of the International Bladder Cancer Group for complete response and duration of complete responseToronto, Ontario--(Newsfile Corp. - ...